Ratio Therapeutics raises $70 million in Series C round to advance radiopharmaceutical pipeline
Ratio Therapeutics has completed a $70 million Series C funding round led by existing and new investors, including Bristol Myers Squibb, Eli Lilly, Catalio Capital Management, and Wasatch Group. The capital will support the advancement of its lead candidate [Ac-225]RTX-2358 in the ATLAS clinical trial for advanced sarcomas and accelerate development of next-generation radioligand therapies. The company plans to expand into new cancer targets and tumour types, leveraging its proprietary Trillium pharmacokinetic tuning technology and Macropa chelator platform. CEO Dr Jack Hoppin emphasized that the funding will be critical for scaling manufacturing capabilities and preparing for future investigational drug filings as Ratio moves closer to commercialization. Ratio’s hybrid production model combines in-house operations with external partners, ensuring flexibility as it scales its pipeline. The company also benefits from strategic collaborations like its partnership with Novartis on SSTR2 radioligand therapy.